Nearly 500 mn doses of Covid-19 vaccine by July 2021, says Harsh Vardhan

He also said that the government was also keeping an eye on immunity data with regard to Covid-19 while finalising these plans

covid, coronavirus, vaccine, drug, pharma
The committee led by V K Paul, member - health, NITI Aayog is drawing up the plan for the entire process of vaccine procurement and distribution.
Ruchika Chitravanshi New Delhi
3 min read Last Updated : Oct 04 2020 | 9:50 PM IST
India is planning to use 400-500 million doses to vaccinate around 250 million people by July 2021 for the coronavirus infection, Health Minister Harsh Vardhan said on Sunday, while laying out the broad outlines of the country’s vaccine strategy.

States have been asked to submit the lists of populations that will be first in line to receive the vaccination, such as frontline health workers and those with underlying health conditions, by October-end. The government has also started the exercise of getting a lowdown on the status of vaccine development. The Centre, said Vardhan, is seeking commitments from vaccine makers to make the maximum number of doses available for India’s inventory and supply chain management. “The government is committed to taking all measures to ensure equitable access to vaccines,” he said.

Three vaccine candidates are the frontrunners in India: Zydus Cadila, Bharat Biotech and Serum Institute for the Oxford-AstraZeneca vaccine. Phase two human clinical trials for Bharat Biotech’s Covaxin and Zydus Cadila’s ZyCoV-D and phase three trials for Oxford-AstraZeneca’s Covishield are underway.

The government has not taken any decision on the clinical trials of Russia’s Sputnik V vaccine yet, Vardhan said.

Besides the vaccines, the government is also taking stock of the cold chain facilities and related infrastructure down to the block level across states, which will be required for vaccine distribution.


Industry experts believe India has a fairly developed cold chain network, especially due to an extensive national immunisation programme.

India has used the Electronic Vaccine Intelligence Network (eVIN) to track information on vaccine supply chain and stocks across the country during the Covid-19 pandemic. This was done to ensure smooth immunisation across the country. This system provides real-time information on stocks and temperatures across registered vaccine storage sites in India. The network has 23,900 digital temperature loggers and 41,420 cold chain handlers for digital record-keeping.

Vardhan said the government is also working on ramping up human resource and training capacity on a massive scale. 

The committee led by V K Paul, member-health, Niti Aayog, is drawing up the plan for the process of vaccine procurement and distribution. “Vaccine procurement is being done centrally and each consignment will be tracked real-time until delivery to ensure it reaches those who need it most,” the minister said.

The government is hoping to have its ducks in a row by the time the vaccines are ready to ensure swift roll-out of the immunisation programme.

Vardhan also said that vaccines will be distributed according to pre-decided priority and in a programmed manner. “To ensure transparency and accountability, details of the entire process will be shared in the coming months.”

The data around immunity already achieved against Covid-19 in the country will be taken into account while finalising the vaccine-related plans. However, the government has not yet shared the total cost of vaccination and ways of financing it.

On September 26, Serum Institute’s chairman Adar Poonawalla tweeted: “Will the government of India have Rs 80,000 crore available, over the next one year? Because that’s what @MoHFW_INDIA needs, to buy and distribute the vaccine to everyone in India. This is the next concerning challenge we need to tackle.”

India’s vaccine making abilities are among the highest in the world and the government has said in the past that even if any other country succeeds in developing a vaccine before us, either India or China will ultimately have to scale it up.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineHarsh VardhanimmunisationNiti AayogRussia

Next Story